You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(688235.SH):將於2023年完成用於一線治療NSCLC的3期AdvanTIG-302試驗入組

格隆匯5月17日丨有投資者向百濟神州(688235.SH)提問:請更新公司在研TIGIT抑制劑歐司珀利單抗的情況?

百濟神州回覆:公司就TIGIT抑制劑歐司珀利單抗在2021年12月與諾華達成進一步合作,授予諾華在指定國家共同開發歐司珀利單抗的獨家的、基於時間的選擇權,諾華可在2023年年底之前行使該權利。該項合作也使得公司可以和合作夥伴共同取得收益、承擔風險。

公司繼續推進正在進行的臨牀項目,將於2023年對多項2期研究進行數據公佈,包括:用於二線治療腫瘤表達PD-(L)1的ESCC(NCT04732494);用於一線治療HCC(NCT04948697);用於一線治療NSCLC(NCT05014815)。公司將於2023年完成用於一線治療NSCLC的3期AdvanTIG-302試驗入組。

公司也將對羅氏TIGIT進一步數據讀出保持密切關注。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account